Evidence map›Paper›PMID 31247009›Full record

ArticlePloS one2019

Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.

Eric N Ouattara, Rachel L MacLean, Christine Danel, Ethan D Borre, Delphine Gabillard, Mingshu Huang, Raoul Moh, A David Paltiel, Serge P Eholié, Rochelle P Walensky and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Eric N OuattaraCentre Inserm 1219, University of Bordeaux, Bordeaux, France.
Rachel L MacLeanMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, United States of America.
Christine DanelCentre Inserm 1219, University of Bordeaux, Bordeaux, France.
Ethan D BorreMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, United States of America.
Delphine GabillardCentre Inserm 1219, University of Bordeaux, Bordeaux, France.
Mingshu HuangMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, United States of America.
Raoul MohProgramme PAC-CI/ANRS Research Site, CHU de Treichville, Abidjan, Côte d'Ivoire.
A David PaltielYale School of Public Health, New Haven, CT, United States of America.
Serge P EholiéProgramme PAC-CI/ANRS Research Site, CHU de Treichville, Abidjan, Côte d'Ivoire.
Rochelle P WalenskyMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, United States of America.
Xavier AnglaretCentre Inserm 1219, University of Bordeaux, Bordeaux, France.
Kenneth A FreedbergMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, United States of America.ORCID 0000-0003-3143-7822
Université de Bordeaux · FRMassachusetts General Hospital · USProgramme PAC-CI · CIBoston University · USBrigham and Women's Hospital · USYale University · US

Funding

Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Optimizing HIV Care in Less Developed CountriesR37AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEDBERG, KENNETH ALAN · 2018 to 2024
$6.6M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR37AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALENSKY, ROCHELLE P. · 2015 to 2019
$3.8M
NIAID NIH HHS R01 AI058736NIAID NIH HHS R01 AI093269NIAID NIH HHS R37 AI093269
6 · The paper itself

Abstract

introductionThe Temprano and START trials provided evidence to support early ART initiation recommendations. We projected long-term clinical and economic outcomes of immediate ART initiation in Côte d'Ivoire.

methodsWe used a mathematical model to compare three potential ART initiation criteria: 1) CD4 <350/μL (ART<350/μL); 2) CD4 <500/μL (ART<500/μL); and 3) ART at presentation (Immediate ART). Outcomes from the model included life expectancy, 10-year medical resource use, incremental cost-effectiveness ratios (ICERs) in $/year of life saved (YLS), and 5-year budget impact. We simulated people with HIV (PWH) in care (mean CD4: 259/μL, SD 198/μL) and transmitted cases. Key input parameters to the analysis included first-line ART efficacy (80% suppression at 6 months) and ART cost ($90/person-year). We assessed cost-effectiveness relative to Côte d'Ivoire's 2017 per capita annual gross domestic product ($1,600).

resultsImmediate ART increased life expectancy by 0.34 years compared to ART<350/μL and 0.17 years compared to ART<500/μL. Immediate ART resulted in 4,500 fewer 10-year transmissions per 170,000 PWH compared to ART<350/μL. In cost-effectiveness analysis, Immediate ART had a 10-year ICER of $680/YLS compared to ART<350/μL, ranging from cost-saving to an ICER of $1,440/YLS as transmission rates varied. ART<500/μL was "dominated" (an inefficient use of resources), compared with Immediate ART. Immediate ART increased the 5-year HIV care budget from $801.9M to $812.6M compared to ART<350/μL.

conclusionsIn Côte d'Ivoire, immediate compared to later ART initiation will increase life expectancy, decrease HIV transmission, and be cost-effective over the long-term, with modest budget impact. Immediate ART initiation is an appropriate, high-value standard of care in Côte d'Ivoire and similar settings.

Indexed as

AdolescentAdultAnti-HIV AgentsBudgetsCD4 Lymphocyte CountCohort StudiesComputer SimulationCost-Benefit AnalysisCote d'IvoireDrug CostsFemaleHealth ResourcesHIV InfectionsHumansLife ExpectancyMaleAnti-HIV Agents

Identifiers

PMID31247009
PMCPMC6597104
OpenAlexW2955767310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.